<DOC>
	<DOCNO>NCT01504776</DOCNO>
	<brief_summary>The purpose study determine safety clinical efficacy combination panobinostat plus bortezomib .</brief_summary>
	<brief_title>Phase I Study Panobinostat + Bortezomib Relapsed and/or Refractory Mantle Cell Lymphoma ( MCL )</brief_title>
	<detailed_description>This phase I single arm , open label , multi-center ( 3 participate site ) dose escalation study oral panobinostat administer Monday-Wednesday-Friday ( MWF ) weekly x 4 week , utilize 3+3 dose scheme ( 15 , 20 , 25 mg ) combination fix dose bortezomib 1.3 mg/m2 administer short intravenous ( IV ) infusion 3-5 second every week x 4 week , represent one cycle . Each week , bortezomib administer IV prior oral dose panobinostat . There sub-investigators participate study enroll sub-sites .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Male female patient age ≥ 18 year old Ability provide write informed consent obtain prior participation study relate procedure perform Patients must adequate hematology/chemistry lab value Echocardiogram ( ECHO ) must demonstrate Left Ventricular Ejection Fraction ( LVEF ) ≥ 50 % . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 Patients previously diagnose MCL base standard criterion least one maximum 4 line therapy currently require treatment Prior therapy autologous allogeneic stem cell transplant permissible . Patients undergone allogeneic transplant evidence graftversushost disease ( GVHD ) immunosuppressive therapy . Autologous allogeneic transplant count one prior therapy . Patients previously treat bortezomib include study Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer Patients need valproic acid medical condition study within 5 day prior first LBH589 ( Panobinostat ) treatment Peripheral neuropathy ≥ Common Toxicity Criteria Adverse Effects ( CTCAE ) grade 2 clinical examination within 14 day randomization Impaired cardiac function clinically significant cardiac disease Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption LBH589 Patients diarrhea &gt; CTCAE grade 2 . Other concurrent severe and/or uncontrolled medical condition ( e.g. , uncontrolled diabetes active uncontrolled infection ) include abnormal laboratory value , could cause unacceptable safety risk compromise compliance protocol Patients use medication relative risk prolong QT interval induce torsade de pointes treatment discontinue switched different medication prior start study drug Patients receive targeted agent within 2 week within 5 halflives agent active metabolite ( whichever longer ) recover side effect therapy . Patients receive either immunotherapy within &lt; 8 week ; chemotherapy within &lt; 4 week ; radiation therapy &gt; 30 % marrowbearing bone within &lt; 2 week prior start study treatment ; yet recover side effect therapy . Patients undergone major surgery ≤ 4 week prior start study drug recover side effect therapy Women pregnant breast feed woman childbearing potential ( WOCBP ) use effective method birth control . WOCBP define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . Women childbearing potential must negative serum pregnancy test within 24hrs receive first dose study medication . Male patient whose sexual partner WOCBP use effective birth control Patients prior malignancy within last 5 year ( except basal squamous cell carcinoma , situ cancer cervix ) Patients known positivity human immunodeficiency virus ( HIV ) ) hepatitis C ; baseline test HIV hepatitis C require Patients significant history noncompliance medical regimen unwilling unable comply instruction give him/her study staff . Allergic reaction bortezomib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>MCL</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Panobinostat</keyword>
</DOC>